These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8642355)

  • 1. ACE inhibitors and renoprotection.
    Peterson K
    J Fam Pract; 1996 May; 42(5):453. PubMed ID: 8642355
    [No Abstract]   [Full Text] [Related]  

  • 2. ACE inhibitors as a shield against diabetic nephropathy.
    Materson BJ
    Arch Intern Med; 1996 Feb; 156(3):239-40. PubMed ID: 8572832
    [No Abstract]   [Full Text] [Related]  

  • 3. Practical problems in the management of hypertension in the diabetic patient.
    O'Hare JP
    J Diabetes Complications; 1996; 10(3):146-8. PubMed ID: 8807462
    [No Abstract]   [Full Text] [Related]  

  • 4. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephropathy in patients with type 2 diabetes mellitus.
    Ritz E; Orth SR
    N Engl J Med; 1999 Oct; 341(15):1127-33. PubMed ID: 10511612
    [No Abstract]   [Full Text] [Related]  

  • 6. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
    Luño J; Valderrábano F
    An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
    [No Abstract]   [Full Text] [Related]  

  • 7. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment.
    Parving HH
    Diabetologia; 1998 Jul; 41(7):745-59. PubMed ID: 9686914
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CARI guidelines. Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes.
    Chadban S; Howell M; Twigg S; Thomas M; Jerums G; Cass A; Campbell D; Nicholls K; Tong A; Mangos G; Stack A; MacIsaac RJ; Girgis S; Colagiuri R; Colagiuri S; Craig J;
    Nephrology (Carlton); 2010 Apr; 15 Suppl 1():S195-203. PubMed ID: 20591031
    [No Abstract]   [Full Text] [Related]  

  • 10. ARBs vs ACE inhibitors for preventing diabetic nephropathy.
    Greenwood V
    J Fam Pract; 2005 May; 54(5):453; discussion 453-4. PubMed ID: 15865904
    [No Abstract]   [Full Text] [Related]  

  • 11. GenoMed research finds ACE inhibitors delay kidney disease.
    Nephrol News Issues; 2002 Jun; 16(7):70. PubMed ID: 12073391
    [No Abstract]   [Full Text] [Related]  

  • 12. Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria.
    Piñol C; Cobos A; Cases A; Esmatges E; Soler J; Closas J; Pascual R; Planas J
    Kidney Int Suppl; 1996 Jun; 55():S85-7. PubMed ID: 8743519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical inquiries. Do ACE inhibitors prevent nephropathy in type 2 diabetes without proteinuria?
    Sferra L; Kelsberg G; Dodson S; Saseen J
    J Fam Pract; 2004 Jan; 53(1):68-9. PubMed ID: 14709273
    [No Abstract]   [Full Text] [Related]  

  • 14. Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?
    Erman A; Boner G; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):365-8. PubMed ID: 11967825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE-I and ARBs in early diabetic nephropathy.
    Mauer M; Zinman B; Gardiner R; Drummond KN; Suissa S; Donnelly SM; Strand TD; Kramer MS; Klein R; Sinaiko AR
    J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):262-9. PubMed ID: 12584670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic nephropathy and renal protective agents.
    Marchiando R; Elston MP
    S D J Med; 1999 Oct; 52(10):385-6. PubMed ID: 10546516
    [No Abstract]   [Full Text] [Related]  

  • 17. Best practice for hypertensive patients with kidney disease.
    de Zeeuw D
    Hosp Med; 2003 Feb; 64(2):96-100. PubMed ID: 12619337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ACE inhibitors and AT-II antagonists--do they protect against renal disease?].
    Rossing P; Parving HH
    Ugeskr Laeger; 2006 Apr; 168(15):1564; author reply1564-5. PubMed ID: 16640990
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin-receptor blockade in renal disease: the hard issues.
    Sica DA
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):469-71. PubMed ID: 15225107
    [No Abstract]   [Full Text] [Related]  

  • 20. Going out to detect incipient diabetic nephropathy rather than waiting until it has supervened--a reversal in policy.
    Parving HH
    Nephrol Dial Transplant; 1996 Sep; 11(9):1728-9. PubMed ID: 8918612
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.